Global HIV Antivirals Market Size study, By Product (Fixed Dose Combinations (FDCs), Integrase Strand Transfer Inhibitors (INSTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Entry Inhibitors - CCR5 co-receptor antagonist, Protease Inhibito

Global HIV Antivirals Market Size study, By Product (Fixed Dose Combinations (FDCs), Integrase Strand Transfer Inhibitors (INSTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Entry Inhibitors - CCR5 co-receptor antagonist, Protease Inhibitors (PIs), Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Regional Forecasts 2022-2028

Global HIV Antivirals Market is valued approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. The HIV Antivirals refers to antiretroviral medicines utilized to hinder the ability of the human immunodeficiency virus (HIV) to multiply in the body. HIV Antivirals are organized into six different classes based on the stage of the HIV life cycle. The US Food and Drug Administration (FDA) approved more than two dozen antiretroviral drugs to treat HIV infection. The growing prevalence of HIV infection and increasing awareness towards HIV treatment options as well as recent product launches and approvals from regulatory authorities are factors that are accelerating the global market demand. For instance, according to World Health Organization (WHO) estimates – as of 2020, 37.7 million individuals were living with HIV. Around 6,80,000 people succumbs to HIV and another 1.5 million individuals acquired HIV. Moreover, as per United Nations Children's Fund (UNICEF) - in 2020, Globally around 1.72 million children aged 0-14 living with HIV. However, only 54 per cent children received life-saving antiretroviral therapy (ART). Furthermore, other recent factors including new product announcements & recent regulatory approvals are likely to influence the growth of Global HIV Antivirals Market. For instance, in July 2020, the U.S. Food and Drug Administration approved North Carolina, US based ViiV Healthcare’s new antiretroviral medication named Rukobia (fostemsavir), intended for adults living with HIV. In addition, in June 2022, Mumbai, India based Cipla Ltd. in collaboration with Geneva, Switzerland based not-for-profit R&D Organization, Drugs for Neglected Diseases initiative (DNDi) launched a new fixed-dose combination of four antiretroviral (ARV) treatment for children living with HIV in South Africa. This new treatment combination is composed of abacavir, lamivudine, lopinavir, and ritonavir and intended for infants and young children. Also, growing healthcare infrastructure in emerging economies and favorable government initiatives across the globe are anticipated to act as a catalyzing factor for the market demand during the forecast period. However, limited access to HIV treatment and rigorous regulatory guidelines for approval of HIV drugs impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global HIV Antivirals Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the rising government funded programs and presence of recent medications approvals in the region. Whereas, Asia Pacific is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as growing healthcare sector and increasing incidences of HIV infections in the region, would create lucrative growth prospects for the global HIV Antivirals Market across the Asia Pacific region.

Major market players included in this report are:
ViiV Healthcare
Gilead Sciences, Inc.
GlaxoSmithKline plc
Merck & Co., Inc.
Johnson & Johnson
Genetech, Inc.
Teva Pharmaceutical Industries Ltd.
AbbVie
Cipla
Pfizer Inc.


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Product:
Fixed Dose Combinations (FDCs)
Integrase Strand Transfer Inhibitors (INSTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry Inhibitors - CCR5 co-receptor antagonist
Protease Inhibitors (PIs)
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global HIV Antivirals Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

ViiV Healthcare
Gilead Sciences, Inc.
GlaxoSmithKline plc
Merck & Co., Inc.
Johnson & Johnson
Genetech, Inc.
Teva Pharmaceutical Industries Ltd.
AbbVie
Cipla
Pfizer Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.